Home Cart Sign in  
Chemical Structure| 1201438-56-3 Chemical Structure| 1201438-56-3

Structure of Duvelisib
CAS No.: 1201438-56-3

Chemical Structure| 1201438-56-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Duvelisib is a selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.

Synonyms: IPI-145; INK1197

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Duvelisib

CAS No. :1201438-56-3
Formula : C22H17ClN6O
M.W : 416.86
SMILES Code : O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5
Synonyms :
IPI-145; INK1197
MDL No. :MFCD15144635
InChI Key :SJVQHLPISAIATJ-ZDUSSCGKSA-N
Pubchem ID :50905713

Safety of Duvelisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Duvelisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, Ki:243 pM

  • p110β

    PI3Kβ, Ki:1564 pM

  • p110δ

    PI3Kδ, Ki:23 pM

In Vitro:

Cell Line
Concentration Treated Time Description References
primary mouse B cells 1 μM 48 hours increased AID expression and CSR PMC5382874
human chronic lymphocytic leukemia (CLL) cell lines (MEC1) 1 μM increased AID expression and genomic instability PMC5382874
ALK+ ALCL cell lines 1 μM 3 hours To evaluate the effect of Duvelisib on ALK+ ALCL cell lines, results showed that Duvelisib inhibited CCL19/21-induced MAPK pathway activation. PMC10804420
μM cells 1 μM 72 hours To evaluate the effect of Duvelisib on μM cell survival, results showed that Duvelisib significantly increased apoptosis in μM cells. PMC5380901
μM1s cells 1 μM 4 hours To evaluate the effect of Duvelisib on AKT phosphorylation, results showed that Duvelisib inhibited AKT phosphorylation. PMC5380901
BMDMs 20 µmol/L 48 hours To investigate the effect of Duvelisib on Akt phosphorylation in BMDMs, results showed that Duvelisib successfully reversed the macrophage phenotype shift induced by mFgfr3 cell supernatant. PMC10722136
gMDSC cells 100 nM 4 hours Treatment with IPI-145 significantly reduced Arg1 and Nos2 transcript levels in gMDSCs and partially reversed the suppressive capacity of gMDSCs on T-cell proliferation. PMC5466078
CLL B cells 0.1 to 1000nM 96 hours To evaluate the effects of PI3K inhibitors on CLL cell survival, results showed that PI3K- δi and duvelisib significantly reduced CLL cell viability PMC10192081
CLL B cells 10−5 to 104 nM 72 hours To evaluate the effects of PI3K inhibitors on CLL cell proliferation, results showed that duvelisib and PI3K-δi significantly inhibited CLL cell proliferation PMC10192081
JURKAT cells 0.1, 1.0, 9.0 μM IPI145 inhibited Akt and S6 phosphorylation PMC6690758
MOLT3 cells 0.1, 1.0, 9.0 μM IPI145 inhibited Akt and S6 phosphorylation PMC6690758
Normal and CLL patient T cells 0.1 to 10 μM 24 hours To assess the potential iμMunomodulatory effects of PI3K inhibitors on T cell survival and function. Results showed that these inhibitors did not compromise the survival of normal or CLL T cells at concentrations of 0.1 to 10 μM, and all inhibitors reduced pAKT levels, indicating PI3K pathway inhibition. PMC7362385

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice pristane-induced plasma cell (PC) tumor model oral ITF2357: 50 mg/kg, Pemetrexed: 100 mg/kg Injected every other day for 20 days increased AID-mediated genomic instability and tumor formation PMC5382874
Mice ALK+ ALCL xenograft model Oral 100 mg/kg Once every 5 days for 4 weeks To evaluate the effect of Duvelisib in combination with Crizotinib on ALK+ ALCL xenograft models, results showed that the combination significantly reduced tumor cell proliferation and increased apoptosis. PMC10804420
NSG mice MM xenograft model intraperitoneal injection 100 mg/kg Twice a week for 4 weeks To evaluate the effect of Duvelisib on MM tumor burden, results showed that Duvelisib significantly reduced tumor burden and improved survival in mice. PMC5380901
C57BL/6J mice MB49 tumor model Oral 15 mg/kg once daily for 10 days To investigate the in vivo antitumor efficacy of Duvelisib in mFgfr3 tumors, results showed that Duvelisib significantly inhibited the growth of mFgfr3 tumors and reversed the macrophage phenotype. PMC10722136
mice MOC1 tumor model oral 2 mg/kg Once daily until the end of the experiment Low-dose IPI-145 monotherapy partially reversed MDSC suppressive capacity and enhanced CD8 TIL infiltration and activation in MOC1 tumor-bearing mice. PMC5466078
NSG mice CLL xenograft model oral gavage 10 mg/kg Single dose To evaluate the effects of duvelisib on CLL cells and CLL-supporting T cells and myeloid cells, results showed that duvelisib significantly reduced the number of CLL cells in the spleen PMC10192081
mice murine T-ALL model oral (GDC0941), intraperitoneal (VCR) Day 1 and 4: 5 mg/kg, Day 8 and 14: 2.5 mg/kg Twice a week for two weeks GDC0941 and VCR combination therapy significantly extended mouse survival PMC6690758
Mice Em-TCL1 mouse model Oral 70 or 100 mg/kg once daily for 3 weeks To evaluate the antitumor efficacy and immunomodulatory effects of PI3K inhibitors in the CLL mouse model. Results showed that idelalisib, duvelisib, and umbralisib significantly reduced CLL burden, but idelalisib- and duvelisib-treated mice displayed increased immune-mediated toxicities, whereas Treg number and function were preserved in umbralisib-treated CLL-bearing mice. PMC7362385

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02158091 Chronic Lymphocytic Leukemia Phase 1 Phase 2 Active, not recruiting July 2021 United States, Massachusetts ... More >> Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01925911 Healthy Phase 1 Completed - United States, Kansas ... More >> PRA International Lenexa, Kansas, United States, 66219 Less <<
NCT03757000 B-cell Lymphoma Recurrent ... More >> B-cell Chronic Lymphocytic Leukemia Less << Phase 1 Recruiting May 30, 2019 China, Beijing ... More >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD    86 10-88140650    songyuqin622@163.com    Contact: Meifeng Tu, MD,PhD    86 10-88121122    44329472@qq.com    Principal Investigator: Yuqin Song, MD,PhD          Sub-Investigator: Meifeng Tu, MD,PhD          Sub-Investigator: Lingyan Ping, MD,PhD          China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD    86 25-83714511    lijianyonglm@126.com    Contact: Wei Xu, MD,PhD    86 25-83714511    xuwei0484@jsph.org.cn    Principal Investigator: Jianyong Li, MD,PhD          Sub-Investigator: Meifeng Tu, MD,PhD          China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD    86 22-23909172    qiulg@ihcams.ac.cn    Contact: Junyuan Qi, MD,PhD    86 22-23909999    qijy@ihcams.ac.cn    Principal Investigator: Lugui Qiu, MD,PhD          Sub-Investigator: Junyuan Qi, MD,PhD Less <<
NCT01549106 Healthy Volunteers Phase 1 Completed - Netherlands ... More >> PRA International Zuidlaren, Netherlands, 9470 AE Less <<
NCT01947777 Healthy Phase 1 Completed - United States, Kansas ... More >> PRA International, Inc Lenexa, Kansas, United States, 66219 Less <<
NCT02158091 - Active, not recruiting - -
NCT02605694 Lymphoma Phase 2 Withdrawn(Sponsor is focusing ... More >>on studies which can enable registration of duvelisib) Less << - United States, Florida ... More >> Miami, Florida, United States, 33133 Less <<
NCT01653756 Asthma Phase 2 Completed - Germany ... More >> Investigational Site Berlin, Germany Investigational Site Grosshansdorf, Germany Investigational Site Wiesbaden, Germany United Kingdom Investigational Site Harrow, United Kingdom Less <<
NCT01851707 Rheumatoid Arthritis Phase 2 Completed - -
NCT02028039 Leukemia Phase 2 Withdrawn - -
NCT01836861 Healthy PHASE1 COMPLETED 2025-05-13 Pharmaceuticals Research Assoc... More >>iation (PRA), Zuidlaren, Netherlands Less <<
NCT02049515 Chronic Lymphocytic Leukemia ... More >> Small Lymphocytic Lymphoma Less << Phase 3 Enrolling by invitation June 2019 -
NCT02204982 Follicular Lymphoma Phase 3 Terminated(Sponsor is focusing... More >> on studies which can enable registration of duvelisib) Less << - Australia, Victoria ... More >> Frankston, Victoria, Australia, 3199 France Bordeaux, France, 33076 Italy Bologna, Italy, 40138 Terni, Italy, 05100 Poland Gdynia, Poland, 81-519 Less <<
NCT01871675 Lymphoma Chro... More >>nic Lymphocytic Leukemia Non-Hodgkin Lymphoma T-cell Lymphoma Less << Phase 1 Completed - United States, Colorado ... More >> The Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Oklahoma Oklahoma University Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37203 Less <<
NCT02004522 Chronic Lymphocytic Leukemia ... More >> Small Lymphocytic Lymphoma Less << Phase 3 Active, not recruiting June 2021 -
NCT01476657 Hematologic Malignancies Phase 1 Terminated(The scope of the pr... More >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Less << - United States, New York ... More >> New York, New York, United States, 10065 United States, Ohio Columbus, Ohio, United States, 43210 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas Houston, Texas, United States, 77030 Less <<
NCT02292225 Lymphocytic Leukemia, Chronic ... More >> Lymphoma, Small Lymphocytic Less << Phase 1 Terminated(The scope of the pr... More >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Less << - United States, California ... More >> La Jolla, California, United States, 92093 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York New Hyde Park, New York, United States, 11042 United States, Ohio Columbus, Ohio, United States, 43210 United States, Texas Houston, Texas, United States, 77030 Canada, Quebec Montreal, Quebec, Canada, H3T 1E2 Less <<
NCT02307461 Healthy Phase 1 Completed - United States, Kansas ... More >> Lenexa, Kansas, United States, 66219 Less <<
NCT02391545 CD20+ Follicular Lymphoma Phase 1 Phase 2 Completed - United States, California ... More >> Los Angeles, California, United States, 90095 Palo Alto, California, United States, 94304 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York Rochester, New York, United States, 14642 United States, Texas Dallas, Texas, United States, 75246 Belgium Kortrijk, Belgium, 8000 Leuven, Belgium, 3000 Wilrijk, Belgium, 2610 France Clermont-Ferrand, France, 63003 Marseille Cedex 05, France, 13385 Pessac, France, 33600 Rouen Cedex 1, France, 76038 Tours Cedex 01, France, 37044 Italy Bologna, Italy, 40138 Varese, Italy, 21100 Spain Badalona, Barcelona, Spain, 8916 Barcelona, Spain, 8097 Madrid, Spain, 28222 Salamanca, Spain, 37007 United Kingdom Leeds, United Kingdom, LS9 7TF London, United Kingdom, NW1 1BU Less <<
NCT02576275 Indolent Non-Hodgkin's Lymphom... More >>a Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma Less << Phase 3 Withdrawn(The scope of the pro... More >>gram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Less << - United States, Connecticut ... More >> Plainville, Connecticut, United States, 06062 United States, Florida Plantation, Florida, United States, 33322 United States, Georgia Thomasville, Georgia, United States, 31792 United States, New York East Setauket, New York, United States, 11733-3456 United States, Tennessee Cookeville, Tennessee, United States, 38501 Knoxville, Tennessee, United States, 37909 United States, Washington Spokane, Washington, United States, 99208 Less <<
NCT02640833 Chronic Lymphocytic Leukemia ... More >> Small Lymphocytic Lymphoma Non-Hodgkin Lymphoma Less << Phase 1 Withdrawn(Study Stopped) February 2021 United States, Arizona ... More >> Site Reference ID/Investigator# 145677 Tucson, Arizona, United States, 85724-5024 United States, Illinois Site Reference ID/Investigator# 147922 Chicago, Illinois, United States, 60611 Site Reference ID/Investigator# 148562 Harvey, Illinois, United States, 60426 United States, Indiana Site Reference ID/Investigator# 148561 Goshen, Indiana, United States, 46526 United States, Maryland Site Reference ID/Investigator# 145674 Baltimore, Maryland, United States, 21287 United States, Massachusetts Site Reference ID/Investigator# 145145 Boston, Massachusetts, United States, 02215 United States, Michigan Site Reference ID/Investigator# 148010 Detroit, Michigan, United States, 48202 United States, Missouri Site Reference ID/Investigator# 147747 St. Louis, Missouri, United States, 63110 United States, New Hampshire Site Reference ID/Investigator# 145146 Lebanon, New Hampshire, United States, 03756 United States, South Carolina Site Reference ID/Investigator# 148559 Greenville, South Carolina, United States, 29605 Less <<
NCT02783625 Lymphoma Rela... More >>psed/Refractory T-cell Lymphomas Less << Phase 1 Recruiting May 2019 United States, California ... More >> Stanford University Medical Center Recruiting Stanford, California, United States, 94305-5408 Contact: Youn Kim, MD    650-498-6000       United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Jacobsen, MD    617-582-9086       United States, Missouri University of Washington School of Medicine in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD    314-362-5654       Principal Investigator: Neha Mehta-Shah, MD          Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD    314-362-5654       Principal Investigator: Neha Mehta-Shah, MD          United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Steven Horwitz, MD    212-639-3045       Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Steven Horwitz, MD    212-639-3045       United States, New York Memorial Sloan Kettering Cancer Center @ Commack Recruiting Commack, New York, United States, 11725 Contact: Steven Horwitz, MD    212-639-3045       Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States Contact: Steven Horwitz, MD    212-639-3045       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Steven Horwitz, MD    212-639-3045       Contact: Alison Moskowitz, MD    212-639-4839       Principal Investigator: Steven Horwitz, MD          Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Steven Horwitz, MD    212-639-3045 Less <<
NCT03372057 Peripheral T-cell Lymphoma Phase 2 Recruiting December 2021 United States, California ... More >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Rosemarie Abary    626-218-8087    rabary@coh.org    Principal Investigator: Jasmine Zain, MD          United States, Illinois Northwestern University - Feinberg School of Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Nick Cornicelli    312-695-0706    nicholas.cornicelli@northwestern.edu    Principal Investigator: Barbara Pro, MD          United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Erin Jeter    617-632-6218    Erin_Jeter@DFCI.HARVARD.EDU    Principal Investigator: Eric Jacobsen, MD          United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kristen McDaniels, BS    314-747-1207    k.mcdaniels@wustl.edu    Principal Investigator: Neha Mehta-Shah, MD          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Nasrin Ahmed    646-449-1311    ahmedn1@mskcc.org    Principal Investigator: Steven Horwitz, MD          University of Rochester Recruiting Rochester, New York, United States, 14627 Contact: Yelena Lerman    585-276-8333    ylerman@urmc.rochester.edu    Contact: Erin Cebula       erin_cebula@urmc.rochester.edu    Principal Investigator: Carla Casulo, MD          United States, Ohio The Ohio State Univeristy Recruiting Columbia, Ohio, United States, 43202 Contact: Pamela Heeter    614-293-9627    pam.heeter@osumc.edu    Principal Investigator: Jonathan Brammer, MD Less <<
NCT02095587 Hepatic Impairment PHASE1 COMPLETED 2025-10-14 Miami, Florida, 33014, United ... More >>States Less <<
NCT03370185 Chronic Lymphocytic Leukemia|S... More >>mall Lymphocytic Lymphoma Less << PHASE2 WITHDRAWN 2025-03-21 Arizona Oncology, Tempe, Arizo... More >>na, 85284, United States|Genesis Cancer Center, Hot Springs, Arkansas, 71913, United States|Moores UC San Diego Cancer Center, La Jolla, California, 92093, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|QUEST Research Institute, Royal Oak, Michigan, 48073, United States|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Summit Medical Group, Morristown, New Jersey, 07932, United States|Medical Oncology Associates PS, WA, Spokane, Washington, 99208, United States Less <<
NCT03534323 Chronic Lymphocytic Leukemia Phase 1 Phase 2 Recruiting June 1, 2024 United States, Massachusetts ... More >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Jacob Soumerai, MD    617-726-2865    jsoumerai@mgh.harvard.edu    Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Jon Arnason, MD    617-667-9920    jarnason@bidmc.harvard.edu    Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Karen Francoeur, RN    617-632-5849    kalowe@partners.org    Principal Investigator: Mattherw S Davids, MD Less <<
NCT01882803 Indolent Non-Hodgkin Lymphoma PHASE2 COMPLETED 2020-11-18 Los Angeles, California, 90095... More >>-6984, United States|Whittier, California, 90603, United States|Denver, Colorado, 80218, United States|Fort Myers, Florida, 39916, United States|Saint Petersburg, Florida, 33705, United States|Tallahassee, Florida, 32308, United States|Atlanta, Georgia, 30322, United States|Chicago, Illinois, 60637, United States|Louisville, Kentucky, 40207, United States|Baltimore, Maryland, 21204, United States|Baltimore, Maryland, 21229, United States|Boston, Massachusetts, 02215, United States|Saint Louis, Missouri, 63110, United States|Howell, New Jersey, 07731, United States|Morristown, New Jersey, 07962, United States|New York, New York, 10021, United States|Rockville Centre, New York, 11510, United States|Canton, Ohio, 44718, United States|Lawton, Oklahoma, 73505, United States|Oklahoma City, Oklahoma, 73104, United States|Philadelphia, Pennsylvania, 01911, United States|Nashville, Tennessee, 37203, United States|Dallas, Texas, 75246, United States|Lynchburg, Virginia, 24501, United States|Lesnoy, Minsk Region, 223040, Belarus|Brest, 224027, Belarus|Minsk, 220013, Belarus|Vitebsk, 210603, Belarus|Gent, 9000, Belgium|Kortrijk, 8500, Belgium|Sofia, 1233, Bulgaria|Sofia, 1407, Bulgaria|Sofia, 1431, Bulgaria|Sofia, 1756, Bulgaria|Toronto, Ontario, M5G 2M9, Canada|Gatineau, Quebec, J8P7H2, Canada|Montreal, Quebec, H3T 1E2, Canada|Brno, 625-00, Czechia|Ostrava-Poruba, 708-52, Czechia|Angers Cedex 09, 49933, France|Bordeaux, 33076, France|Clermont-Ferrand, 63000, France|Marseille, 13005, France|Pierre Benite, 69495, France|Tbilisi, 0186, Georgia|Budapest, 1083, Hungary|Budapest, 1122, Hungary|Debrecen, 4032, Hungary|Bologna, 40138, Italy|Brescia, 25123, Italy|Busto Arsizio, 21052, Italy|Genova, 16132, Italy|Meldola, 47014, Italy|Milano, 20162, Italy|Modena, 41124, Italy|Orbassano, 10043, Italy|Parma, 43100, Italy|Ravenna, 48121, Italy|Rimini, 47923, Italy|Varese, 21100, Italy|Barcelona, 08036, Spain|Madrid, 28222, Spain|Salamanca, 37007, Spain|Cardiff, CF 14 4XW, United Kingdom|Chelsea, United Kingdom|Liverpool, L7 8XP, United Kingdom|London, NW1 2PG, United Kingdom|London, W1G 6AD, United Kingdom|Sutton, SM2 5PT, United Kingdom Less <<
NCT02711852 Hematologic Malignancy PHASE2 COMPLETED 2020-05-04 Denver, Colorado, 80218, Unite... More >>d States|Sarasota, Florida, 34232, United States|Nashville, Tennessee, 37203, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States|Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia, Terni, Umbria, 05100, Italy Less <<
NCT02598570 Lymphoma Phase 1 Completed - Japan ... More >> Site Reference ID/Investigator# 141826 Aichi, Japan Site Reference ID/Investigator# 141595 Fukuoka, Japan Site Reference ID/Investigator# 141594 Tokyo, Japan Less <<
NCT01882803 Indolent Non-Hodgkin Lymphoma PHASE2 COMPLETED 2020-11-18 Los Angeles, California, 90095... More >>-6984, United States|Whittier, California, 90603, United States|Denver, Colorado, 80218, United States|Fort Myers, Florida, 39916, United States|Saint Petersburg, Florida, 33705, United States|Tallahassee, Florida, 32308, United States|Atlanta, Georgia, 30322, United States|Chicago, Illinois, 60637, United States|Louisville, Kentucky, 40207, United States|Baltimore, Maryland, 21204, United States|Baltimore, Maryland, 21229, United States|Boston, Massachusetts, 02215, United States|Saint Louis, Missouri, 63110, United States|Howell, New Jersey, 07731, United States|Morristown, New Jersey, 07962, United States|New York, New York, 10021, United States|Rockville Centre, New York, 11510, United States|Canton, Ohio, 44718, United States|Lawton, Oklahoma, 73505, United States|Oklahoma City, Oklahoma, 73104, United States|Philadelphia, Pennsylvania, 01911, United States|Nashville, Tennessee, 37203, United States|Dallas, Texas, 75246, United States|Lynchburg, Virginia, 24501, United States|Lesnoy, Minsk Region, 223040, Belarus|Brest, 224027, Belarus|Minsk, 220013, Belarus|Vitebsk, 210603, Belarus|Gent, 9000, Belgium|Kortrijk, 8500, Belgium|Sofia, 1233, Bulgaria|Sofia, 1407, Bulgaria|Sofia, 1431, Bulgaria|Sofia, 1756, Bulgaria|Toronto, Ontario, M5G 2M9, Canada|Gatineau, Quebec, J8P7H2, Canada|Montreal, Quebec, H3T 1E2, Canada|Brno, 625-00, Czechia|Ostrava-Poruba, 708-52, Czechia|Angers Cedex 09, 49933, France|Bordeaux, 33076, France|Clermont-Ferrand, 63000, France|Marseille, 13005, France|Pierre Benite, 69495, France|Tbilisi, 0186, Georgia|Budapest, 1083, Hungary|Budapest, 1122, Hungary|Debrecen, 4032, Hungary|Bologna, 40138, Italy|Brescia, 25123, Italy|Busto Arsizio, 21052, Italy|Genova, 16132, Italy|Meldola, 47014, Italy|Milano, 20162, Italy|Modena, 41124, Italy|Orbassano, 10043, Italy|Parma, 43100, Italy|Ravenna, 48121, Italy|Rimini, 47923, Italy|Varese, 21100, Italy|Barcelona, 08036, Spain|Madrid, 28222, Spain|Salamanca, 37007, Spain|Cardiff, CF 14 4XW, United Kingdom|Chelsea, United Kingdom|Liverpool, L7 8XP, United Kingdom|London, NW1 2PG, United Kingdom|London, W1G 6AD, United Kingdom|Sutton, SM2 5PT, United Kingdom Less <<
NCT03961672 Recurrent Chronic Lymphocytic ... More >>Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-06-15 City of Hope Medical Center, D... More >>uarte, California, 91010, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97239, United States Less <<
NCT05044039 Non-hodgkin Lymphoma|Acute Lym... More >>phocytic Leukemia Less << PHASE1 RECRUITING 2030-05-31 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT05923502 Follicular Lymphoma|Chronic Ly... More >>mphocytic Leukemia/Small Lymphocytic Lymphoma|Richter Syndrome|Marginal Zone Lymphoma|Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma Less << NOT_YET_RECRUITING 2027-11-30 -
NCT04038359 Indolent Non-Hodgkin Lymphoma PHASE2 COMPLETED 2023-07-24 Florida Cancer Specialists - F... More >>ort Myers, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists & Research Institute - Lecanto, Lecanto, Florida, 34461, United States|Mid-Florida Cancer Centers, Orange City, Florida, 32763, United States|Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, 60611, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|FN Hradec Kralove, Hradec Králové, 500 05, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Universitaetsklinikum Bonn A?R, Bonn, 53127, Germany|Oncology Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forli, 47014, Italy|IEO - Istituto Europeo di Oncologia, IRCCS, Milano, 20141, Italy|AUSL di Reggio Emilia IRCCS, Arcispedale Santa Maria Nuova di Reggio Emilia, Reggio Emilia, 42123, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, 05100, Italy|Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fondazione Macchi, Varese, 21100, Italy|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center - Oncology, Seoul, 05505, Korea, Republic of|Samsung Medical Center - Hematology-Oncology, Seoul, 06351, Korea, Republic of|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Slupsk, Pomorskie, 76-200, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Centrum Medyczne Pratia Poznan, Skórzewo, 60-185, Poland|State Budgetary Healthcare Institution of Moscow City Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Healthcare of Moscow City, Moscow, 108814, Russian Federation|City Clinical Hospital n.a. Botkin, Moscow, 125284, Russian Federation|First Saint-Petersburg State Medical University n.a. I.P. Pavlov, Sankt-Peterburg, 197022, Russian Federation|NHS Greater Glasgow & Clyde - CRUK Clinical Trials Unit, Glasgow, G12 0YN, United Kingdom|Royal Liverpool Hospital [Hematology/Transfusion Medicine], Liverpool, L7 8XP, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, M20 4BX, United Kingdom Less <<
NCT04707079 Follicular Lymphoma PHASE2 UNKNOWN 2022-03-31 Shanghai Ruijin Hospital, Shan... More >>ghai, Shanghai, 200020, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.99mL

2.40mL

1.20mL

23.99mL

4.80mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories